Big Vaccine Update Gives JNJ a Leg Up

Optimism surrounding the stock has been high

Deputy Editor
Feb 24, 2021 at 9:03 AM
facebook twitter linkedin

Johnson & Johnson (NYSE:JNJ) is in the spotlight this morning, after the U.S. Food and Drug Administration (FDA) deemed the drugmaker's one-shot Covid-19 vaccine safe and effective. A panel of independent experts to the FDA are slated to meet at the end of the week to make a final approval decision. In response, the security is up 1.4% at $162.65 in early trading. 

JNJ has been cooling since hitting its record high of $173.65 in late January. The equity did attempt a second rally back to these levels earlier this month, but this was met with resistance at the $168 level. The 50-day moving average looks to be coming in as a leg of support, however, and JNJ has managed to remain just north of its year-to-date breakeven, sporting a roughly 2% lead. 

Analysts have remained optimistic. All but three of the 13 in coverage consider Johnson & Johnson stock to be a "buy" or better. Meanwhile, the 12-month consensus price target of $185.44 is a 14.3% premium to current levels. 

Options traders have echoed this sentiment. This is per JNJ's 50-day call/put volume ratio of International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 89% of readings from the past year. This means this heavy penchant for bullish bets is unusual.

Similarly, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.44 stands higher than only 10% of readings from the past 12 months. In simpler terms, this suggests short-term traders have rarely been more call-biased on JNJ.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners